Drugs / tenofovir disproxil fumarate
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06963710 Comparator | Jul 2025 → Mar 2027 expected | chronic hepatitis B virus infection | Aligos Therapeutics | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tenofovir disproxil fumarate | “This is a Phase 2 study to evaluate efficacy and safety of 48 weeks of oral once daily monotherapy with ALG-000184 versus tenofovir disproxil fumarate (TDF) for chronic HBV infection.” NCT06963710 ↗ |
| Known as | TDF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06963710 ↗ |